Charles Schwab
CLSD

Charles Schwab’s Clearside Biomedical CLSD Stock Holding History

Charles Schwab’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,348
Closed -$19.2K – 3484
2024
Q4 		$19.2K Hold
1,348
– – ﹤0.01% 3487
2024
Q3 		$25.7K Hold
1,348
– – ﹤0.01% 3472
2024
Q2 		$26.3K Hold
1,348
– – ﹤0.01% 3572
2024
Q1 		$30.9K Hold
1,348
– – ﹤0.01% 3409
2023
Q4 		$23.7K Hold
1,348
– – ﹤0.01% 3472
2023
Q3 		$17.6K Hold
1,348
– – ﹤0.01% 3527
2023
Q2 		$22.6K Hold
1,348
– – ﹤0.01% 3544
2023
Q1 		$21K Hold
1,348
– – ﹤0.01% 3505
2022
Q4 		$22.6K Hold
1,348
– – ﹤0.01% 3487
2022
Q3 		$23K Hold
1,348
– – ﹤0.01% 3467
2022
Q2 		$30K Hold
1,348
– – ﹤0.01% 3472
2022
Q1 		$47K Hold
1,348
– – ﹤0.01% 3535
2021
Q4 		$56K Hold
1,348
– – ﹤0.01% 3502
2021
Q3 		$122K Sell
1,348
-533
-28% -$47K ﹤0.01% 3364
2021
Q2 		$138K Buy
1,881
+1,086
+137% +$50.5K ﹤0.01% 3281
2021
Q1 		$30K Sell
795
-977
-55% -$49.1K ﹤0.01% 3476
2020
Q4 		$73K Hold
1,772
– – ﹤0.01% 3335
2020
Q3 		$41K Hold
1,772
– – ﹤0.01% 3289
2020
Q2 		$50K Buy
+1,772
New +$52.2K ﹤0.01% 3261
2019
Q2 		– Sell
-3,473
Closed -$72K – 3227
2019
Q1 		$72K Hold
3,473
– – ﹤0.01% 3101
2018
Q4 		$56K Sell
3,473
-542
-13% -$25.4K ﹤0.01% 3128
2018
Q3 		$371K Hold
4,015
– – ﹤0.01% 2940
2018
Q2 		$644K Buy
4,015
+1,442
+56% +$243K ﹤0.01% 2714
2018
Q1 		$415K Hold
2,573
– – ﹤0.01% 2780
2017
Q4 		$271K Hold
2,573
– – ﹤0.01% 2908
2017
Q3 		$338K Hold
2,573
– – ﹤0.01% 2834
2017
Q2 		$352K Buy
2,573
+1,640
+176% +$197K ﹤0.01% 2811
2017
Q1 		$112K Hold
933
– – ﹤0.01% 3002
2016
Q4 		$126K Buy
+933
New +$234K ﹤0.01% 3024

Other funds holding CLSD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab's CLSD Position: Q1 2025 in Review

Charles Schwab sold out of Clearside Biomedical (CLSD) in Q1 2025, closing a stake of 1,348 shares — an estimated $19.2K sold.

Charles Schwab first reported a position in CLSD in Q4 2016 and held it in 29 quarters. The position peaked at $644K in Q2 2018. 43 funds tracked by Wall St. Rank hold CLSD as of Q1 2025.

  • Charles Schwab reported no remaining Clearside Biomedical position as of Q1 2025 after selling out during the quarter.
  • Charles Schwab sold 1,348 Clearside Biomedical shares in Q1 2025, an estimated $19.2K.
  • Charles Schwab first reported a position in Clearside Biomedical in Q4 2016 and held it in 29 quarters.
  • Charles Schwab's Clearside Biomedical position peaked at $644K in Q2 2018.
  • 43 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2025.

Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.